Former GW Pharmaceuticals executive Rupert Haynes has joined FSD Pharma Inc of Toronto as chief executive to help the Canadian company advance development of its cannabis-based pharmaceutical products.
Mr Haynes was previously head of global marketing at GW Pharmaceuticals where he oversaw strategic development of the company’s cannabinoid products including Epidiolex, a recently approved treatment for Dravet syndrome.
Before this, he held senior positions at Swedish Orphan Biovitrum AB, UCB SA and the UK-based subsidiaries of Bristol-Myers Squibb Co and Pharmacia & Upjohn (now Pfizer Inc). In his new job, Mr Haynes is based in the UK.
FSD Pharma announced the appointment on 26 November 2018.
Copyright 2018 Evernow Publishing Ltd